Coherus Oncology (CHRS) Stock Overview
A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
CHRS Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Coherus Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.94 |
| 52 Week High | US$2.43 |
| 52 Week Low | US$0.66 |
| Beta | 0.87 |
| 1 Month Change | 23.66% |
| 3 Month Change | -14.53% |
| 1 Year Change | -34.25% |
| 3 Year Change | -91.11% |
| 5 Year Change | -94.60% |
| Change since IPO | -92.54% |
Recent News & Updates
Coherus Oncology, Inc.'s (NASDAQ:CHRS) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Jul 24
Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues
May 18Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates
May 15Recent updates
Coherus Oncology, Inc.'s (NASDAQ:CHRS) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Jul 24Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues
May 18Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates
May 15Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs
Apr 17
UDENYCA Divestiture And LOQTORZI Progress Will Forge Opportunity Amid Risks
UDENYCA divestiture and headcount reduction will strengthen the balance sheet and improve margins through reduced expenses.Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop
Mar 28Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings
Mar 24There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise
Dec 21Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
Dec 16Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%
Nov 06Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive
Sep 22Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Aug 13Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S
Aug 07Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
May 31Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now
May 23Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Mar 21Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive
Feb 03Coherus BioSciences: FDA Approvals Spice Up The Pipeline
Jan 17Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues
Dec 20The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically
May 13Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3
Sep 19Shareholder Returns
| CHRS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.8% | -3.3% | -0.6% |
| 1Y | -34.3% | -12.5% | 16.8% |
Return vs Industry: CHRS underperformed the US Biotechs industry which returned -11.4% over the past year.
Return vs Market: CHRS underperformed the US Market which returned 15.7% over the past year.
Price Volatility
| CHRS volatility | |
|---|---|
| CHRS Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CHRS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CHRS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 221 | Denny Lanfear | www.coherus.com |
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors.
Coherus Oncology, Inc. Fundamentals Summary
| CHRS fundamental statistics | |
|---|---|
| Market cap | US$112.46m |
| Earnings (TTM) | US$49.15m |
| Revenue (TTM) | US$272.25m |
Is CHRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHRS income statement (TTM) | |
|---|---|
| Revenue | US$272.25m |
| Cost of Revenue | US$118.77m |
| Gross Profit | US$153.48m |
| Other Expenses | US$104.34m |
| Earnings | US$49.15m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.42 |
| Gross Margin | 56.38% |
| Net Profit Margin | 18.05% |
| Debt/Equity Ratio | -160.7% |
How did CHRS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/31 13:23 |
| End of Day Share Price | 2025/07/31 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Coherus Oncology, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |